Confo Therapeutics raises €30 million; Waylivra receives approval from EU; endpoint met for Merck's Belsomra in PhIII trial
→ In an investment led by BioGeneration Ventures and co-led by Wellington Partners, with Fund+ and Perceptive Advisors stepping in, Confo Therapeutics announced today that it has raised €30 million ($33.4 million) in Series A financing. The company said that the funds will be allocated to use towards accelerating its ConfoBody-enabled drug discovery activities and to develop its pipeline of GPCR modulating compounds to produce drug candidates for clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.